Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP)Defense World · Oct 8, 2026
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)Defense World · Oct 4, 2026
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And MoreSeeking Alpha · Sep 11, 2026Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | $0.43 | $2.76 | Beat |
| May 19, 2026 | – | $0.91 | |
| Mar 26, 2026 | -$0.08 | -$0.06 | Beat |
| Nov 13, 2025 | -$0.04 | $1.13 | Beat |
| Aug 14, 2025 | -$0.04 | -$0.05 | Miss |
| May 15, 2025 | -$0.03 | -$0.19 | Miss |